Literature DB >> 1563017

Role of interferon gamma and tumour necrosis factor alpha in monocyte-mediated cytostasis and cytotoxicity against a human histiocytic lymphoma cell line.

A A van de Loosdrecht1, G J Ossenkoppele, R H Beelen, M G Broekhoven, M M Langenhuijsen.   

Abstract

In view of cellular adoptive immunotherapy we have studied monocyte-mediated cytostasis and cytotoxicity against U 937 cells, a human histiocytic lymphoma cell line. Highly purified human monocytes and monocyte-derived macrophages were activated with interferon gamma (IFN) or tumour necrosis factor alpha (TNF) to antileukemic immune effector cells. Antileukemic activity of human monocytes was dependent on monocyte differentiation into macrophages and on a dose- and time-dependent activation with IFN or TNF. Maximum cytostasis of 97.0 +/- 0.7% (mean +/- SEM) (conventional [3H]dT uptake assay) and 81.9 +/- 5.3% cytotoxicity (modified MTT assay) of U 937 cells was obtained by monocytes activated with 100 U/ml IFN for at least 24 h at an effector-to-target-cell ratio of 10. U 937 cells premodified with IFN showed an increase in susceptibility to monocyte-mediated cytotoxicity. U 937 cells premodified with TNF were almost resistant to monocyte-mediated cytotoxicity while activated monocytes maintained their cytotoxic potential. These data show that IFN and TNF are potent activators of monocyte-mediated cytotoxicity. Furthermore, IFN and TNF might be involved in the regulation of the susceptibility of leukemic cells to lysis by interactions with monocytes or macrophages.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1563017     DOI: 10.1007/bf01741750

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  40 in total

1.  Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Authors:  M C Alley; D A Scudiero; A Monks; M L Hursey; M J Czerwinski; D L Fine; B J Abbott; J G Mayo; R H Shoemaker; M R Boyd
Journal:  Cancer Res       Date:  1988-02-01       Impact factor: 12.701

2.  CD antigens 1989.

Authors:  W Knapp; B Dörken; P Rieber; R E Schmidt; H Stein; A E von dem Borne
Journal:  Blood       Date:  1989-09       Impact factor: 22.113

3.  Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay.

Authors:  J A Plumb; R Milroy; S B Kaye
Journal:  Cancer Res       Date:  1989-08-15       Impact factor: 12.701

Review 4.  Secretory products of macrophages.

Authors:  C F Nathan
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

5.  A randomized phase I/II study of continuous versus intermittent intravenous interferon gamma in patients with metastatic melanoma.

Authors:  M S Ernstoff; T Trautman; C A Davis; S D Reich; P Witman; J Balser; S Rudnick; J M Kirkwood
Journal:  J Clin Oncol       Date:  1987-11       Impact factor: 44.544

6.  Macrophage tumor necrosis factor-alpha release is induced by contact with some tumors.

Authors:  J D Hasday; E M Shah; A P Lieberman
Journal:  J Immunol       Date:  1990-07-01       Impact factor: 5.422

7.  Immunotherapy of a murine lymphoma by adoptive transfer of syngeneic macrophages activated with bisantrene.

Authors:  B S Wang; A L Lumanglas; F E Durr
Journal:  Cancer Res       Date:  1986-02       Impact factor: 12.701

8.  Gamma-IFN induces a differential expression of HLA-DR, DQ and DP antigens on peripheral blood myeloid leukemic blasts at various stages of differentiation.

Authors:  M Lecchi; E Lovisone; C Genetta; D Peruccio; L Resegotti; P Richiardi
Journal:  Leuk Res       Date:  1989       Impact factor: 3.156

9.  Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages.

Authors:  J L Urban; H M Shepard; J L Rothstein; B J Sugarman; H Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

10.  Cytotoxic effector cell function at different stages of human monocyte-macrophage maturation.

Authors:  R Andreesen; J Osterholz; K J Bross; A Schulz; G A Luckenbach; G W Löhr
Journal:  Cancer Res       Date:  1983-12       Impact factor: 12.701

View more
  2 in total

1.  In vitro purging of clonogenic leukaemic cells from human bone marrow by interferon-gamma-activated monocytes.

Authors:  A A van de Loosdrecht; G J Ossenkoppele; R H Beelen; M G Broekhoven; K M Schweitzer; M M Langenhuijsen
Journal:  Cancer Immunol Immunother       Date:  1994-05       Impact factor: 6.968

2.  Enhanced killing capacity of human Kupffer cells after activation with human granulocyte/macrophage-colony-stimulating factor and interferon gamma.

Authors:  B Schuurman; G Heuff; R H Beelen; S Meyer
Journal:  Cancer Immunol Immunother       Date:  1994-09       Impact factor: 6.968

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.